Cosmos Health Inc COSM 深 滬
已收盤 02-06 16:00:00 美东时间
0.4495
+0.010
+2.23%
華盛通- 最 高0.4653
- 今 開0.435
- 成交量 83.23万股
- 最 低 0.422
- 昨 收 0.4397
- 總市值 1678.70万
- 52周最高 1.32
- 市盈率 靜 --
- 換手率 2.23%
- 52周最低 0.2801
- 委 比 24.74%
- 總股本 3734.60万
- 歷史最高 23.84
- 量 比 1.19
- 振 幅 9.85%
- 歷史最低 0.2801
- 每 手 1
- 風險率 0.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Watching Cosmos Health; Shares See Volume, Zacks Small-Cap Research Gives Stock $4.50 Price Valuation
Initiation of Coverage with $4.50 Per Share ValuationZacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis, reflecting projected revenue growth,
01-15 00:30
Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
Zacks initiates coverage on Cosmos Health Inc. with a $4.50 valuation, highlighting its diversified healthcare model, U.S. market expansion, and vertical integration. Projected revenue growth from $64.4 million in 2025 to over $130 million by 2027 reflects strong financial performance. The Company’s acquisitions of ZipDoctor, Cloudscreen, and strategic investments in AI-driven R&D, nutraceuticals, and telehealth services position it for long-term...
01-14 16:25
Cosmos Health's Cana Laboratories Subsidiary Signs Agreement To Produce PathMuscle For Libytec Pharmaceutical
Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered
01-05 22:33
Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
<p>Cosmos Health Inc. subsidiary Cana Laboratories has signed a manufacturing and supply agreement with Libytec Pharmaceutical S.A. to produce and distribute PathMuscle, an advanced generic pharmaceutical product, in Greece. PathMuscle is a fixed-dose combination of thiocolchicoside and paracetamol, designed to treat painful muscle spasms associated with musculoskeletal disorders. The agreement includes firm minimum production volumes of 591,500 ...
01-05 14:30
Cosmos Health shares are trading higher after a Form 4 filing showed its CEO purchased 88,314 shares at an average price of $0.49.
Cosmos Health shares are trading higher after a Form 4 filing showed its CEO pu...
2025-12-23 02:18
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
Cosmos Health Inc. CEO Greg Siokas has increased his ownership by acquiring 301,101 shares between November 19-28, 2025, bringing his total holdings to 6,459,985 shares this year. Siokas emphasized his belief in the company's potential despite valuation pressures, following strong Q3 2025 results. The diversified healthcare group operates in pharmaceuticals, nutraceuticals, and telehealth, with a focus on global expansion and innovative product d...
2025-12-02 17:15
Cosmos Health Q3 Adj. EPS $(0.02) Up From $(0.34) YoY, Sales $17.110M Up From $12.411M YoY
Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.02) per share. This is a 94.12 percent increase over losses of $(0.34) per share from the same period last year. The company reported $17.110 million in sales
2025-11-17 22:17
COSMO Pharmaceuticals N.V. (0RGI) Gets a Buy from Kepler Capital
In a report released on October 21, Nicolas Pauillac from Kepler Capital mainta...
2025-10-23 09:47
Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million
Cosmos Health Inc. (NASDAQ:COSM) has purchased an additional $200,000 worth of Ethereum (ETH), bringing its total investment in ETH to $2 million. This purchase was made under the company's $300 million digital assets facility, aimed at diversifying and strengthening its portfolio. CEO Greg Siokas highlighted this as a significant step in the company's digital asset expansion strategy, emphasizing its commitment to leveraging the facility for lon...
2025-10-21 16:10
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced on October 16, 2025, that it has regained compliance with Nasdaq's minimum bid price rule of $1.00 per share after its stock closed above this threshold for 18 consecutive business days. CEO Greg Siokas highlighted that this achievement was organic, reflecting the company's strategic initiatives and strengthened fundamentals. cosmos health continues to focus on creating value ...
2025-10-16 12:00
